{
  "signal_id": "repurpose-rn-44-01",
  "compound": "Compound RN-44 (example)",
  "proposed_species": [
    "feline"
  ],
  "proposed_condition": "Chronic kidney disease",
  "summary_hypothesis": "Research hypothesis: Compound RN-44 may warrant evaluation for feline CKD fibrosis pathways.",
  "why_failed_originally": {
    "summary": "Human CKD trial reported insufficient bioavailability within the planned dosing window.",
    "failure_type": "pk",
    "key_points": [
      "Insufficient bioavailability at planned dosing window."
    ]
  },
  "why_it_might_work_in_animals": {
    "summary": "Feline CKD progression windows and management context may support alternative dosing strategies under research protocols.",
    "key_points": [
      "Different progression tempo and management context in cats.",
      "Potential for earlier intervention windows."
    ]
  },
  "evidence": {
    "vet_strength": "moderate",
    "key_docs": [
      "pmid:EXAMPLE-VET-202",
      "ctgov:EXAMPLE-CKD-002"
    ],
    "notes": "Evidence is research-only and requires validation."
  },
  "risk": {
    "overall_risk": 55,
    "key_flags": [
      "Renal clearance uncertainty (severity 3)"
    ]
  },
  "novelty_vectors": [
    "new_species",
    "new_indication"
  ],
  "confidence_score": 50,
  "addressability_score": 60,
  "translation_risk": 40,
  "score_breakdown": {
    "vet_evidence": 22,
    "species_rationale": 13,
    "addressability": 12,
    "recency_volume": 4,
    "risk_penalty": 1
  },
  "recommended_next_steps": [
    "retrospective_review",
    "in_vitro",
    "pilot_study"
  ],
  "provenance": {
    "agent_run_ids": [
      "fixture-run-rn-44"
    ],
    "timestamps": [
      "2026-02-04T00:00:00.000Z"
    ]
  },
  "reasoning_summaries": {
    "executive_summary": [
      "Compound RN-44: human CKD trial limited by PK/bioavailability.",
      "Feline CKD progression windows may allow alternative research dosing strategies.",
      "Veterinary evidence is moderate but limited to retrospective signals.",
      "Risk profile is moderate and requires renal safety review."
    ],
    "failure_summary": "Human CKD trial showed insufficient bioavailability; failure type: pk.",
    "species_benefit_summary": [
      {
        "species": "feline",
        "summary": "Feline CKD progression tempo may permit alternative research dosing windows."
      }
    ],
    "evidence_summary": "Veterinary evidence is moderate with retrospective signals; limitations remain.",
    "risk_summary": "Risk profile is moderate (55/100) with renal clearance uncertainty.",
    "next_steps_summary": "Next steps: retrospective_review, in_vitro, pilot_study (research-only)."
  },
  "disclaimer": "Research hypothesis only; not medical advice."
}